Details

Autor(en) / Beteiligte

• Hézode, Christophe
• Forestier, Nicole
• Dusheiko, Geoffrey
• Ferenci, Peter
• Pol, Stanislas
• Goeser, Tobias
• Bronowicki, Jean-Pierre
• Bourlière, Marc
• Gharakhanian, Shahin
• Bengtsson, Leif
• McNair, Lindsay
• George, Shelley
• Kieffer, Tara
• Kwong, Ann
• Kauffman, Robert S
• Alam, John
• Pawlotsky, Jean-Michel
• Zeuzem, Stefan

Titel

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

Ist Teil von

• The New England journal of medicine, 2009-04, Vol.360 (18), p.1839-1850

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this phase 2 trial in patients infected with HCV genotype 1, three regimens including telaprevir, a specific inhibitor of the HCV serine protease, were tested. One such regimen (telaprevir for 12 weeks and peginterferon and ribavirin for 24 weeks) resulted in a higher rate of sustained virologic response than the control regimen (48 weeks of peginterferon and ribavirin). Telaprevir caused severe rash in some patients. In this trial in patients infected with HCV genotype 1, three regimens including telaprevir were tested. One regimen (telaprevir for 12 weeks and peginterferon and ribavirin for 24 weeks) resulted in a higher rate of sustained virologic response than the control regimen. Hepatitis C virus (HCV) is the most common infectious cause of chronic liver disease in Europe and the United States. Chronic hepatitis C may result in life-threatening complications, including cirrhosis and hepatocellular carcinoma. Antiviral therapy may result in a sustained virologic response, characterized by an undetectable HCV RNA level 24 weeks after the end of therapy, which correlates with a long-term clinical benefit. In patients infected with HCV genotype 1, the most common genotype worldwide, the standard combination of peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of only 40 to 50%. 1 – 3 A . . .